Bioxytran announces PCT publication of two COVID-19 treatment patents and USPTO trademark approval for ProLectin

BIOXYTRAN, INC

PCT published patent WO 2022/099052 for polysaccharides treating SARS-CoV-2, filed Nov 2021.
PCT published patent WO 2022/099061 for IV-administered pectin polysaccharides treating SARS-CoV-2.
USPTO approved trademark 'ProLectin' for publication in Trademark Official Gazette on June 28, 2022.
Both patents claim priority date of November 6, 2020.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.